Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDO siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
IDO siRNA refers to small interfering RNA molecules designed to silence the expression of Indoleamine 2,3-dioxygenase 1 (IDO1). IDO1 is an immunosuppressive enzyme that catabolizes the essential amino acid tryptophan into kynurenine, a metabolite that inhibits T-cell function and promotes an immunosuppressive tumor microenvironment. By utilizing the RNA interference (RNAi) pathway, IDO siRNA specifically targets and degrades IDO1 mRNA, leading to a reduction in IDO1 protein levels. In preclinical research, such as the study of glioblastoma (GBM), IDO siRNA is frequently employed as a tool to investigate the metabolic and non-metabolic roles of IDO1 in tumor progression and immune evasion, helping to distinguish between enzyme-dependent and enzyme-independent immunosuppressive mechanisms.
- Other names
- IDO1 siRNAIDO-1 siRNAIDO 1 siRNAindoleamine 2,3-dioxygenase 1 siRNA
02
Targets
IDO1 (Indoleamine 2,3-dioxygenase 1)
Beyond the preview
Go deeper on IDO siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDO siRNA.